CORRECTION article

Front. Pharmacol., 14 August 2020

Sec. Pharmacology of Anti-Cancer Drugs

Volume 11 - 2020 | https://doi.org/10.3389/fphar.2020.01178

Corrigendum: Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase

  • 1. Henan Joint International Research Laboratory of Veterinary Biologics Research and Application, Anyang Institute of Technology, Anyang, China

  • 2. Institute of Environmental Safety and Human Health, Wenzhou Medical University, Wenzhou, China

  • 3. Laboratory of Natural Product Extraction, China-US (Henan) Hormel Cancer Institute, Zhengzhou, China

  • 4. College of Basic Medical, Yunnan University of Chinese Medicine, Kunming, China

  • 5. Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, China

  • 6. Yunnan Province Key Laboratory for Nutrition and Food Safety in Universities, Kunming, Yunnan, China

Xin Cai was not included as an author, and Xiaoying Zhang was incorrectly included as an author in the published article. The corrected Author Contributions Statement appears below.

Statements

Author contributions

XF designed research, performed research and wrote the paper; JT analyzed the data; MF extracted Eupafolin from Ay Tsao; JW expressed Histone H3 protein; XC, ZJ performed animal research andanalyzed data; SL, KZ designed research and analyzed data.

Furthermore, there was a mistake in Figure 1D as published. The TOPK western picture has an extra strip. The corrected Figure 1 appears below.

Figure 1

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

eupafolin, esophagus cancer, TOPK, inhibitor, Ay Tsao

Citation

Fan X, Tao J, Cai X, Fredimoses M, Wu J, Jiang Z, Zhang K and Li S (2020) Corrigendum: Eupafolin Suppresses Esophagus Cancer Growth by Targeting T-LAK Cell-Originated Protein Kinase Protein Kinase. Front. Pharmacol. 11:1178. doi: 10.3389/fphar.2020.01178

Received

22 February 2020

Accepted

20 July 2020

Published

14 August 2020

Volume

11 - 2020

Edited by

Jiang-Jiang Qin, Zhejiang Chinese Medical University, China

Reviewed by

Qiang Wang, Nanjing Drum Tower Hospital, China

Updates

Copyright

*Correspondence: Kunpeng Zhang, ; Shude Li,

This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics